For years, the medical community has operated under a cautious assumption: that rapid weight loss, particularly through pharmacological intervention, might come at a cost to male reproductive health. But as GLP-1 receptor agonists like semaglutide and liraglutide become standard treatments for obesity, the data is beginning to tell a different story.

New research presented this week at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, suggests that these medications do not harm male hormones or fertility. In fact, the findings indicate that for men with obesity-related low testosterone, GLP-1s may actually help restore hormonal balance and improve sperm quality by addressing the metabolic root cause of the dysfunction.

The Shift from Replacement to Restoration

Researchers at the University Hospitals Coventry and Warwickshire and Warwick Medical School conducted a systematic review of randomized controlled trials to evaluate the impact of GLP-1s on male reproductive function. By analyzing five clinical trials involving men aged 18 to 65, the team sought to determine whether these drugs—designed to regulate blood sugar and curb appetite—had unintended consequences for testicular health.

The results were encouraging. Rather than suppressing testosterone or impairing sperm production, the studies showed stable or improved hormone levels. In one 24-week study of semaglutide, participants saw improvements in sperm morphology—the shape and structure of the sperm—alongside better cholesterol profiles. A separate 16-week study of liraglutide demonstrated that men with obesity and low testosterone experienced an increase in hormone levels, with better overall health outcomes than those treated with testosterone replacement therapy alone.

"This work supports a shift away from prescribing testosterone replacement in men with obesity and low testosterone," said Pratibha Natesh, an endocrinologist at Warwick Medical School and the study’s lead author. "Instead, we are looking toward treating the underlying cause—excess weight and poor metabolic health—which can naturally restore hormone levels and preserve fertility."

Why Metabolic Health Matters for Reproduction

Obesity is a known disruptor of the endocrine system. Excess adipose tissue can lead to the conversion of testosterone into estrogen, creating a hormonal environment that is hostile to sperm production and libido. By targeting the metabolic drivers of obesity, GLP-1s appear to break this cycle.

However, researchers are quick to urge nuance. While the outcomes are positive, the body of evidence remains relatively small. The studies reviewed varied in design and duration, meaning that while the current data is promising, it is not yet definitive.

"Physicians should keep in mind that most of the reproductive benefits observed are likely indirect," Natesh noted. "GLP-1s have not been evaluated as primary treatments for male infertility or hypogonadism, and larger, better-designed studies are still needed to fully understand the long-term effects on male fertility."

What Experts Say

The medical community is watching these developments closely. Endocrinologists have long struggled with the trade-offs of testosterone replacement therapy, which can effectively boost energy and mood but often suppresses the body's natural sperm production.

If GLP-1s can achieve similar symptomatic relief by improving metabolic health without the side effects of exogenous hormones, it could represent a significant change in how clinicians approach men's health. The focus is moving toward systemic health rather than isolated hormone management. By stabilizing blood sugar and reducing systemic inflammation, these drugs may be creating a more hospitable environment for reproductive function than previously understood.

Key Takeaways

  • A systematic review of five clinical trials found no evidence that GLP-1 agonists negatively impact male hormones, sexual function, or sperm quality.
  • Research suggests that by treating obesity, GLP-1s may indirectly improve testosterone levels and sperm morphology in men with metabolic-related infertility.
  • Experts emphasize that these drugs are not currently approved as fertility treatments, and larger studies are required to confirm these preliminary findings.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.